Kronos Bio Inc
44 articles about Kronos Bio Inc
-
Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
5/17/2022
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, announced participation in the H.C. Wainwright Global Investment Conference.
-
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress
5/12/2022
Kronos Bio, Inc. announced that its two novel investigational spleen tyrosine kinase inhibitors, entospletinib and lanraplenib, will be featured in poster presentations at the European Hematology Association 2022 Congress, being held June 9-12 in Vienna.
-
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
5/4/2022
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, reported recent business progress and first quarter 2022 financial results.
-
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
4/8/2022
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, shared preclinical data on its internally discovered, highly selective, oral cyclin dependent kinase 9 inhibitor, KB-0742, adding to evidence that the compound has the potential to treat certain MYC-amplified and transcriptionally addicted solid tumors.
-
Now, Kosacz is helping to guide the company’s experimental oncology treatments toward regulatory approval.
-
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
3/8/2022
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that it will present preclinical data on its internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor, KB-0742, in four poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.
-
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
3/1/2022
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the Cowen 42nd Annual Health Care Conference, a virtual event taking place March 7-9, 2022.
-
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results
2/24/2022
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, reported recent business progress and fourth-quarter and full-year 2021 financial results.
-
Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development
2/1/2022
Kronos Bio, Inc. today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice president, Clinical Development.
-
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
12/6/2021
Kronos Bio, Inc. today announced that the first patient has been dosed in the registrational Phase 3 AGILITY clinical trial of entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK), in combination with standard of care anthracycline and cytarabine (7+3) chemotherapy.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
11/29/2021
Kronos Bio, Inc. today announced positive data from the ongoing Phase 1/2 clinical trial of KB-0742, the company’s internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors.
-
Kronos Bio Announces Participation in Upcoming Investor Conferences - Nov 24, 2021
11/24/2021
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that members of the management team will participate in fireside chats at the following investor conferences.
-
Kronos Bio Reports Recent Business Progress and Third-Quarter 2021 Financial Results
11/9/2021
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, reported recent business progress and third-quarter financial results.
-
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform
11/8/2021
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics tools.
-
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology
11/4/2021
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that Charles Lin, Ph.D., Senior Vice President, Biology, will participate in the Emerging Trends and Therapeutics in Oncology panel at the BMO Biopharma Spotlight Series on Monday, November 8 at 3:25 p.m. Eastern Time.
-
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021Preliminary clinical data from Phase 1/2 study still anticipated in Q4
9/30/2021
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
-
BioSpace Movers & Shakers, Sept. 24
9/24/2021
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.